目的 研究青春期特发性矮小症男性患儿采用重组人生长激素联合来曲唑对改善其预测终身高的影响。方法 将河北省儿童医院2015年5月—2019年5月收诊的青春期特发性矮小症男性患儿60例,采用简单分组法分为两组,其中30例为对照组(采用rhGH治疗),另外30例为实验组(采用rhGH联合来曲唑治疗),两组患儿均治疗1年,收集分析两组患儿治疗期间体格发育、生长速率、骨代谢指标改善情况和不良事件发生情况。结果 两组患儿治疗前骨龄、身高、骨代谢指标差异无统计学意义(P＞0.05),治疗1年后,实验组患儿骨龄、骨碱性磷酸酶(BALP)含量低于对照组(t=6.537、9.290,P＜0.05),骨钙素(BGP)、Ⅰ型胶原氨基酸延长肽(PINP)、Vit-D含量明显高于对照组(t=4.501、4.269、9.230,P＜0.05);预测终身高明显高于对照组(t=2.833,P＜0.05),生长速率、不良反应发生率差异无统计学意义(P＞0.05)。结论 来曲唑可以改善青春期的特发性矮小症男性患儿的预测终身高。
Abstract
Objective To study the efficacy of recombinant human growth hormone (rhGH) combined with letrozole on the improvement of the predicted final height in male children with adolescent idiopathic short stature (ISS). Methods Totally 60 male children diagnosed with adolescent idiopathic short stature admitted in Children's Hospital of Hebei Province from May 2015 to May 2019 were enrolled in this study and were divided into two groups by simple grouping method,with 30 cases in each group. The control group was treated with rhGH,while the experiment group was treated with rhGH and letrozole. Both groups were treated for one year. The improvement of physical development,growth rate,bone metabolism index and occurrence of adverse events were collected and analyzed. Results There were no significant differences in bone age,height and bone metabolism indexes between the two groups before treatment (P>0.05). After 1 year of treatment,the bone age and bone alkaline phosphatase(BALP) level of the experiment group were lower than those of the control group (t=6.537,9.290,P<0.05),and the levels of bone glaprotein(BGP),procollagen Ⅰ N-terminal peptide(PINP) and vitamin D of the experimental group were significantly higher than those of the control group (t=4.501,4.269,9.230,P<0.05). The predicted final height value was significantly higher in experiment group (t=2.833,P<0.05). There were no significant differences in growth rate and adverse reactions between the two groups (P<0.05). Conclusion Letrozole can improve the predicted final height of male children with adolescent idiopathic short stature.
关键词
特发性矮小症 /
rhGH /
来曲唑 /
预测终身高
Key words
idiopathic short stature /
recombinant human growth hormone /
letrozole /
the predicted final height
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 梁小红,谭迪,简杨湄.特发性矮小症患儿血清25(OH)D、IGF-1水平与体质量的相关性[J].海南医学,2020,31(7):841-844.
[2] 舒静娜,祁建凤.重组人生长激素对特发性矮小症患儿胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3的影响[J].中国妇幼保健,2020,35(3):486-488.
[3] 王慧,庄昭明.重组人生长激素联合芳香化酶抑制剂治疗特发性矮小症的效果及安全性[J].中外医学研究,2020,18(8):32-34.
[4] 中华医学会儿科学分会内分泌遗传代谢学组.矮身材儿童诊治指南[J].中华儿科杂志,2008,46(6):428-443.
[5] 张绍岩,刘丽娟,吴真列,等. 中国人手腕骨发育标准-中华05 I.TW3-C RUS、TW3-C腕骨和RUS-CHN方法[J]. 中国运动医学杂志,2006,25(5):509-516.
[6] 陈俊芬,张星星. rhGH联合营养支持治疗特发性矮小症患儿的疗效及对胰岛素样生长因子水平的影响[J]. 中国现代医药杂志,2019,21(7):58-60.
[7] 陈佳音,方洁,赵余丹.特发性矮小患儿NPR3基因多态性与重组人生长激素疗效的相关性[J].中国妇幼保健,2019,34(19):4509-4511.
[8] 王晓宁.芳香化酶抑制剂联合rhGH治疗男性特发性矮小症患儿的疗效观察[J].国际内分泌代谢杂志,2019,39(5):298-301.
[9] 郭艳艳,蒋成霞,姚兰,等.不同剂量重组人生长激素治疗对特发性矮小症患儿身高、体重以及血清IGF-1和IGFBP-3表达的影响[J].解放军医药杂志,2020,32(3):44-47.
[10] Alzahrani AK,Algethami AK,Barnawi G, et al. Differences in response to recombinant growth hormone therapy on height gain in patients with idiopathic short stature Vs.patients with growth hormone deficiency[J].Cureus,2020,12(3):e7319.
[11] 李想,乐原.基因重组人生长激素治疗特发性矮小症患儿的临床疗效及安全性研究[J]. 锦州医科大学学报,2018,39(2):20-22.
[12] 王秋兰.重组人生长激素对儿童生长激素缺乏症和特发性矮小症的效果评价[J].中国实用医药,2020,15(7):167-169.
[13] 乔晓红.芳香化酶抑制剂在儿科领域应用研究进展[J].世界临床药物,2020,41(3):160-165.
[14] 张莹,陈瑞敏,杨晓红,等.重组人生长激素联合来曲唑治疗男性青春期矮小临床分析[J].中国实用儿科杂志,2019,34(9):775-779.
[15] 张先来.基因重组人生长激素联合来曲唑治疗大骨龄矮小儿童的疗效研究[J].中国妇幼健康研究,2017,28(S4):495-496.
基金
河北省卫生健康委青年科技课题(20190843)
PDF(506 KB)
